Goldman has recently initiated Arrowhead Pharmaceuticals Inc (ARWR) stock to Neutral rating, as announced on June 5, 2024, according to Finviz. Earlier, on December 4, 2023, BofA Securities had ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Arrowhead Pharmaceuticals (ARWR – Research ...

Strategic Sarepta partnership and FDA filing position Arrowhead for a transformative leap in RNAi therapeutics ...

Arrowhead Pharmaceuticals' stock rallied 17% due to significant pipeline developments and strategic partnerships. Learn more ...

Bernstein lowered the firm’s price target on Arrowhead (ARWR) to $24 from $27 and keeps a Market Perform rating on the shares. The company’s ...

Shares of Arrowhead Pharmaceuticals Inc. ($ARWR) and Sarepta Therapeutics Inc. ($SRPT) climbed on Wednesday despite Wall ...

Stock futures edged lower on Tuesday as sentiment took a hit after President-elect Donald Trump said he would raise tariffs ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) had its target price cut by Piper Sandler from $62.00 to $45.00 in a ...

Investors in Arrowhead Pharmaceuticals Inc (Symbol: ARWR) saw new options become available this week, for the June 2025 expiration. One of the key inputs that goes into the price an option buyer ...

Short interest in Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) increased during the last reporting period, rising from 9.33M to 9.39M. This put 8.86% of the company's publicly available shares short.

In this article, we are going to take a look at where Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) stands against the other NASDAQ stocks. Potomac Wealth Advisors president Mark Avallone joined CNBC's ...